National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA; Pritzker School of Medicine, The University of Chicago, Chicago, Illinois, USA.
National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.
J Invest Dermatol. 2024 May;144(5):969-977. doi: 10.1016/j.jid.2024.01.011. Epub 2024 Mar 26.
Atopic dermatitis (AD) is a multifactorial, heterogeneous disease characterized by epidermal barrier dysfunction, immune system dysregulation, and skin microbiome alterations. Skin microbiome studies in AD have demonstrated that disease flares are associated with microbial shifts, particularly Staphylococcus aureus predominance. AD-associated S. aureus strains differ from those in healthy individuals across various genomic loci, including virulence factors, adhesion proteins, and proinflammatory molecules-which may contribute to complex microbiome barrier-immune system interactions in AD. Different microbially based treatments for AD have been explored, and their future therapeutic successes will depend on a deeper understanding of the potential microbial contributions to the disease.
特应性皮炎(AD)是一种多因素、异质性疾病,其特征为表皮屏障功能障碍、免疫系统失调和皮肤微生物组改变。AD 的皮肤微生物组研究表明,疾病发作与微生物转移有关,特别是金黄色葡萄球菌优势。AD 相关的金黄色葡萄球菌菌株与健康个体的菌株在多个基因组位置存在差异,包括毒力因子、黏附蛋白和促炎分子——这可能导致 AD 中复杂的微生物组-免疫系统相互作用。人们已经探索了针对 AD 的不同基于微生物的治疗方法,其未来的治疗成功将取决于对微生物对疾病潜在贡献的更深入理解。